Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Yap TA, et al. Among authors: pollard j. J Clin Oncol. 2020 Sep 20;38(27):3195-3204. doi: 10.1200/JCO.19.02404. Epub 2020 Jun 22. J Clin Oncol. 2020. PMID: 32568634 Free PMC article. Clinical Trial.
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ. Williamson CT, et al. Among authors: pollard jr. Nat Commun. 2016 Dec 13;7:13837. doi: 10.1038/ncomms13837. Nat Commun. 2016. PMID: 27958275 Free PMC article.
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.
Hall AB, Newsome D, Wang Y, Boucher DM, Eustace B, Gu Y, Hare B, Johnson MA, Milton S, Murphy CE, Takemoto D, Tolman C, Wood M, Charlton P, Charrier JD, Furey B, Golec J, Reaper PM, Pollard JR. Hall AB, et al. Among authors: pollard jr. Oncotarget. 2014 Jul 30;5(14):5674-85. doi: 10.18632/oncotarget.2158. Oncotarget. 2014. PMID: 25010037 Free PMC article.
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours.
Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R. Middleton MR, et al. Among authors: pollard j. Br J Cancer. 2021 Aug;125(4):510-519. doi: 10.1038/s41416-021-01405-x. Epub 2021 May 26. Br J Cancer. 2021. PMID: 34040175 Free PMC article. Clinical Trial.
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
Knegtel R, Charrier JD, Durrant S, Davis C, O'Donnell M, Storck P, MacCormick S, Kay D, Pinder J, Virani A, Twin H, Griffiths M, Reaper P, Littlewood P, Young S, Golec J, Pollard J. Knegtel R, et al. Among authors: pollard j. J Med Chem. 2019 Jun 13;62(11):5547-5561. doi: 10.1021/acs.jmedchem.9b00426. Epub 2019 May 16. J Med Chem. 2019. PMID: 31074988
Development of pharmacodynamic biomarkers for ATR inhibitors.
Chen T, Middleton FK, Falcon S, Reaper PM, Pollard JR, Curtin NJ. Chen T, et al. Among authors: pollard jr. Mol Oncol. 2015 Feb;9(2):463-72. doi: 10.1016/j.molonc.2014.09.012. Epub 2014 Oct 13. Mol Oncol. 2015. PMID: 25459351 Free PMC article.
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R, Martin SE, Guha R, Ormanoglu P, Pfister TD, Reaper PM, Barnes CS, Jones J, Charlton P, Pollard JR, Morris J, Doroshow JH, Pommier Y. Jossé R, et al. Among authors: pollard jr. Cancer Res. 2014 Dec 1;74(23):6968-79. doi: 10.1158/0008-5472.CAN-13-3369. Epub 2014 Sep 30. Cancer Res. 2014. PMID: 25269479 Free PMC article.
Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase.
Fordham SE, Blair HJ, Elstob CJ, Plummer R, Drew Y, Curtin NJ, Heidenreich O, Pal D, Jamieson D, Park C, Pollard J, Fields S, Milne P, Jackson GH, Marr HJ, Menne T, Jones GL, Allan JM. Fordham SE, et al. Among authors: pollard j. Blood Adv. 2018 May 22;2(10):1157-1169. doi: 10.1182/bloodadvances.2017015214. Blood Adv. 2018. PMID: 29789314 Free PMC article.
1,123 results